Bile LeakNCT05141942
The Need for Repeat ERCP After Endoscopic Treatment of Postsurgical Biliary Leaks
An observational study of Bile Leak, run by University of Calgary at 1 site in Canada.
Trial summary
Post-surgical biliary leaks are relatively common after surgeries associated with hepatobiliary health. Left untreated, biliary leaks can lead to significant morbidity. Biliary leaks are most often successfully managed endoscopically, by way of performing an ERCP (endoscopic retrograde cholangio-pancreatography)… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Bile Leak
- What is being tested?
- Endoscopic Retrograde Cholangiopancreatography (ERCP)
- Type of treatment
- Surgery or procedure
- How many people
- 200 participants
- Where
- 1 siteCanada
- Study dates
- 19 Nov 2019to 30 Jun 2026
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients having ERCP for suspected post-surgical biliary leak;
Who may be able to join
- Patients having ERCP for suspected post-surgical biliary leak;
- age 18 years or older
- able to give informed consent to involvement.
Who cannot join
- Unable or unwilling to provide informed consent;
- age < 18 years;
- non-surgical biliary leak;
- previous ERCP with sphincterotomy;
- previous treatment or attempted treatment of biliary leak;
- unsuccessful initial ERCP.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Validation of a Clinical Prediction Rule to Determine the Need for Repeat ERCP After Endoscopic Treatment of Postsurgical Biliary Leaks
Post-surgical biliary leaks are relatively common after surgeries associated with hepatobiliary health. Left untreated, biliary leaks can lead to significant morbidity. Biliary leaks are most often successfully managed endoscopically, by way of performing an ERCP (endoscopic retrograde cholangio-pancreatography) procedure. These procedures help manage the bile leak by decreasing pressure at the opening of the common bile duct and promoting bile flow into the small bowel (rather than out the leak) via stent insertion.
Guidelines published by the American Society for Gastrointestinal Endoscopy (ASGE) report that stents are generally placed for 4 to 6 weeks and recommend longer intervals for more complex leaks. However, formal recommendations concerning the modality of biliary stent removal do not exist.
Read more
One option is performing a repeat ERCP when removing the stent. While comprehensive, this exposes the patient to additional radiation, and requires additional fluoroscopy resources and/or technicians. Furthermore, ERCPs are less available, especially in smaller centers, and are costly. A second option is a gastroscopy with simple stent removal has, given the low probability of requiring repeat intervention, the relatively low procedural cost, and the relatively favorable adverse event profile, and easier accessibility compared to ERCP procedures.
A simple, safe and reliable prediction rule was developed retrospectively to identify patients in whom biliary stent removal via gastroscopy could be safely performed, as opposed to repeat ERCP. A positive result using the rule requires satisfaction of four non-invasive clinical markers: (1) a normal post-surgical serum alkaline phosphatase value, (2) bile leak 'type C' at initial ERCP (a small or absent leak with no other biliary pathology), (3) a bile leak caused by laparoscopic cholecystectomy, and (4) a time between initial and follow-up endoscopy of 4 to 8 weeks. Validating this prediction rule prospectively could have implications on patient safety by decreasing ERCP-related adverse events, and could also have important implications with regard to health resource utilization.
Read the detailed description
The previously developed prediction rule will be applied in a prospective fashion to consecutive patients undergoing ERCP for suspected post-surgical biliary leak. The same variables will be measured as in the initial study, but in this study, a research assistant (RA) will prospectively enter data and follow up with patients. For the purposes of this study, a second ERCP will be planned for stent removal and repeat cholangiogram (as per current practice). The sequence of procedures will be as follows:
Initial ERCP Visit:
- The patient is referred to PLC Endoscopy Unit for consideration of ERCP procedure for indication of post-surgical biliary leak and is booked by the attending advanced/therapeutic endoscopist on call as appropriate, as per the standard of care.
- Once verbal and written consent to approach has been given to their admitting nurse, patients will be approached by the RA prior to their procedure to discuss the actively enrolling study, and to answer any potential questions.
- If the patient agrees to participate, the informed consent form(s) is/are signed and witnessed. If the patient decides not to participate, the ERCP proceeds as per the usual standard of care (and the sequence that follows does not apply).
- The RA collects relevant patient-related and pre-procedural data through combination of direct patient interview and subsequent review of the medical records. Variables to be collected include:
- age
- gender
- presence of imaging evidence showing bile leak
- type of surgery performed
- time from surgery to ERCP
- Given that the patient will have already had an intravenous (IV) catheter placed on admission to the Endoscopy Unit (for purposes of receiving sedation or anesthesia during the procedure), a laboratory technician arrives to draw bloodwork from the patient to collect the following variables. If all following bloodwork has already been drawn for the patient within the preceding 24 hours prior to the procedure, no additional bloodwork will be drawn.
- complete blood count (CBC), including white blood cell count (WBC)
- gamma-glutamyl transferase (GGT)
- alkaline phosphatase (ALP)
- alanine aminotransferase (ALT)
- aspartate aminotransferase (AST)
- total and direct bilirubin
- international normalized ratio (INR)
- The patient is then met by the endoscopist performing the procedure to discuss the risks and benefits of the procedure and to have the patient sign informed consent for the procedure. The patient enters the endoscopy/fluoroscopy room and the procedure commences.
- During the procedure, peri-procedural data are recorded by the RA by direct observation, and/or, if necessary, in consultation with the procedural physician(s) and/or nurse(s). Variables to be collected include:
- stent length placed
- stent caliber placed
- presence or absence of other pathology (stones, strictures, other)
- extent of leak
- large (defined by the presence of early extravasation of contrast from the leak source prior to opacification of the intrahepatic bile ducts) ii. small (all others) e. location of biliary leak on cholangiography: i. cystic duct remnant ii. accessory bile duct iii. intrahepatic, left or right ducts iv. common hepatic or bile ducts v. no leak found vi. uncertain/ not described f. type of leak i. Type A (large or common bile duct leaks) ii. Type B (no leak observed or small leak, but other pathology observed) iii. Type C (no leak observed or small leak with no other biliary pathology observed)
- After the procedure is complete, the patient is moved to the recovery room for observation. Depending on their disposition and the course of the procedure, observation times and protocols differ. During this stage, the RA collects any relevant post-procedural data, and any missing pre- or peri-procedural data.
- Any peri- or immediate post-procedural adverse event is recorded.
- The patient is examined by the endoscopist prior to discharge and provided with written post-procedure information, including a phone number to call in the event of any issues.
- The RA meets with the patient prior to their discharge from the unit to answer any final potential questions.
- The patient is booked for repeat ERCP procedure as per standard current practices, usually between 6-8 weeks, for stent removal and repeat cholangiogram to rule out residual leak.
- At 30 days post-procedure, the RA reviews the medical record for occurrence of any adverse event(s), in addition to calling the patient to inquire about any unplanned visits to healthcare facilities. Adverse events of interest include:
- pancreatitis
- bleeding
- perforation
- cholangitis and/or sepsis (not present prior to the procedure)
- pain not meeting the definition of any of the above that requires repeat unplanned presentation to a healthcare facility
- At 6 months post index procedure, any repeat or recurrent leaks and/or repeat ERCP procedures are captured.
- Conditions
- Bile Leak
- Being tested
- Endoscopic Retrograde Cholangiopancreatography (ERCP)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Endoscopic Retrograde Cholangiopancreatography (ERCP)Procedure or surgery
Endoscopic procedure employed to manage biliary and pancreatic diseases
What is being measured
The primary outcome is the main question the study is designed to answer.
Absence of persistent bile leak
On repeat endoscopic evaluation absence of persistent bile leak or additional pathology will be evaluated
Measured: immediate
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2021
- Study start19 Nov 2019
- Primary completion31 Mar 2026
- Study completion30 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bile LeakStudies of the same condition, open and under way.
- More trials run by University of CalgaryThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- University of Calgary
- Sponsor type
- University, hospital or other
- Collaborators
- McGill University, Queen's University, Island Health, Victoria, BC, University of Ottawa, Halton Healthcare Oakville
- Responsible party
- Sponsor
- Investigators
- Nauzer Forbes, MD, MSc, Principal investigator, University of Calgary
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05141942
- Sponsor's protocol ID
- REB18-2072
- Status last verified
- Apr 2026
- First submitted
- 19 Nov 2021
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Patient-specific data will be in a de-identified encrypted secure format whenever shared.
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation of a Clinical Prediction Rule to Determine the Need for Repeat ERCP After Endoscopic Treatment of Postsurgical Biliary Leaks
- ClinicalTrials.gov ID
- NCT05141942
- Acronym / sponsor ID
- REB18-2072
- Conditions
- Bile Leak
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- University of CalgaryUniversity, hospital or other
- Collaborators
- McGill University, Queen's University, Island Health, Victoria, BC, University of Ottawa, Halton Healthcare Oakville
- Study start
- 19 Nov 2019 (actual)
- Primary completion
- 31 Mar 2026 (actual)
- Study completion
- 30 Jun 2026 (estimated)
- First posted
- 2 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Post-surgical biliary leaks are relatively common after surgeries associated with hepatobiliary health. Left untreated, biliary leaks can lead to significant morbidity. Biliary leaks are most often successfully managed endoscopically, by way of performing an ERCP (endoscopic retrograde cholangio-pancreatography) procedure. These procedures help manage the bile leak by decreasing pressure at the opening of the common bile duct and promoting bile flow into the small bowel (rather than out the leak) via stent insertion.
Guidelines published by the American Society for Gastrointestinal Endoscopy (ASGE) report that stents are generally placed for 4 to 6 weeks and recommend longer intervals for more complex leaks. However, formal recommendations concerning the modality of biliary stent removal do not exist.
One option is performing a repeat ERCP when removing the stent. While comprehensive, this exposes the patient to additional radiation, and requires additional fluoroscopy resources and/or technicians. Furthermore, ERCPs are less available, especially in smaller centers, and are costly. A second option is a gastroscopy with simple stent removal has, given the low probability of requiring repeat intervention, the relatively low procedural cost, and the relatively favorable adverse event profile, and easier accessibility compared to ERCP procedures.
A simple, safe and reliable prediction rule was developed retrospectively to identify patients in whom biliary stent removal via gastroscopy could be safely performed, as opposed to repeat ERCP. A positive result using the rule requires satisfaction of four non-invasive clinical markers: (1) a normal post-surgical serum alkaline phosphatase value, (2) bile leak 'type C' at initial ERCP (a small or absent leak with no other biliary pathology), (3) a bile leak caused by laparoscopic cholecystectomy, and (4) a time between initial and follow-up endoscopy of 4 to 8 weeks. Validating this prediction rule prospectively could have implications on patient safety by decreasing ERCP-related adverse events, and could also have important implications with regard to health resource utilization.
Detailed description
The previously developed prediction rule will be applied in a prospective fashion to consecutive patients undergoing ERCP for suspected post-surgical biliary leak. The same variables will be measured as in the initial study, but in this study, a research assistant (RA) will prospectively enter data and follow up with patients. For the purposes of this study, a second ERCP will be planned for stent removal and repeat cholangiogram (as per current practice). The sequence of procedures will be as follows:
Initial ERCP Visit:
- The patient is referred to PLC Endoscopy Unit for consideration of ERCP procedure for indication of post-surgical biliary leak and is booked by the attending advanced/therapeutic endoscopist on call as appropriate, as per the standard of care.
- Once verbal and written consent to approach has been given to their admitting nurse, patients will be approached by the RA prior to their procedure to discuss the actively enrolling study, and to answer any potential questions.
- If the patient agrees to participate, the informed consent form(s) is/are signed and witnessed. If the patient decides not to participate, the ERCP proceeds as per the usual standard of care (and the sequence that follows does not apply).
- The RA collects relevant patient-related and pre-procedural data through combination of direct patient interview and subsequent review of the medical records. Variables to be collected include:
- age
- gender
- presence of imaging evidence showing bile leak
- type of surgery performed
- time from surgery to ERCP
- Given that the patient will have already had an intravenous (IV) catheter placed on admission to the Endoscopy Unit (for purposes of receiving sedation or anesthesia during the procedure), a laboratory technician arrives to draw bloodwork from the patient to collect the following variables. If all following bloodwork has already been drawn for the patient within the preceding 24 hours prior to the procedure, no additional bloodwork will be drawn.
- complete blood count (CBC), including white blood cell count (WBC)
- gamma-glutamyl transferase (GGT)
- alkaline phosphatase (ALP)
- alanine aminotransferase (ALT)
- aspartate aminotransferase (AST)
- total and direct bilirubin
- international normalized ratio (INR)
- The patient is then met by the endoscopist performing the procedure to discuss the risks and benefits of the procedure and to have the patient sign informed consent for the procedure. The patient enters the endoscopy/fluoroscopy room and the procedure commences.
- During the procedure, peri-procedural data are recorded by the RA by direct observation, and/or, if necessary, in consultation with the procedural physician(s) and/or nurse(s). Variables to be collected include:
- stent length placed
- stent caliber placed
- presence or absence of other pathology (stones, strictures, other)
- extent of leak
- large (defined by the presence of early extravasation of contrast from the leak source prior to opacification of the intrahepatic bile ducts) ii. small (all others) e. location of biliary leak on cholangiography: i. cystic duct remnant ii. accessory bile duct iii. intrahepatic, left or right ducts iv. common hepatic or bile ducts v. no leak found vi. uncertain/ not described f. type of leak i. Type A (large or common bile duct leaks) ii. Type B (no leak observed or small leak, but other pathology observed) iii. Type C (no leak observed or small leak with no other biliary pathology observed)
- After the procedure is complete, the patient is moved to the recovery room for observation. Depending on their disposition and the course of the procedure, observation times and protocols differ. During this stage, the RA collects any relevant post-procedural data, and any missing pre- or peri-procedural data.
- Any peri- or immediate post-procedural adverse event is recorded.
- The patient is examined by the endoscopist prior to discharge and provided with written post-procedure information, including a phone number to call in the event of any issues.
- The RA meets with the patient prior to their discharge from the unit to answer any final potential questions.
- The patient is booked for repeat ERCP procedure as per standard current practices, usually between 6-8 weeks, for stent removal and repeat cholangiogram to rule out residual leak.
- At 30 days post-procedure, the RA reviews the medical record for occurrence of any adverse event(s), in addition to calling the patient to inquire about any unplanned visits to healthcare facilities. Adverse events of interest include:
- pancreatitis
- bleeding
- perforation
- cholangitis and/or sepsis (not present prior to the procedure)
- pain not meeting the definition of any of the above that requires repeat unplanned presentation to a healthcare facility
- At 6 months post index procedure, any repeat or recurrent leaks and/or repeat ERCP procedures are captured.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 6 Months
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients having ERCP for suspected post-surgical biliary leak;
Key inclusion criteria (3 listed)
- Patients having ERCP for suspected post-surgical biliary leak;
- age 18 years or older
- able to give informed consent to involvement.
Key exclusion criteria (6 listed)
- Unable or unwilling to provide informed consent;
- age < 18 years;
- non-surgical biliary leak;
- previous ERCP with sphincterotomy;
- previous treatment or attempted treatment of biliary leak;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Endoscopic Retrograde Cholangiopancreatography (ERCP)Endoscopic procedure employed to manage biliary and pancreatic diseases | Procedure or surgery | – |
Primary outcome
Absence of persistent bile leak
Time frame: immediate
On repeat endoscopic evaluation absence of persistent bile leak or additional pathology will be evaluated
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
- Individual participant dataSharing planned: Yes. Patient-specific data will be in a de-identified encrypted secure format whenever shared.
Related trials for Bile Leak
Recruiting
Prevention of Bile Leakage After Liver Resection in Children
Postoperative Bile Leak, Focal Liver Lesions
Not yet recruiting
Routine White Test for Early Detection of Bile Leak in Elective Liver Resection (DELiveR Trial)
Bile Leak, Liver Resection
Not yet recruiting
Impact of Intraoperative PTCD Catheter Retention Versus Removal on Postoperative Short-term Outcomes After Pancreaticoduodenectomy in Obstructive Jaundice
Obstructive Jaundice, Pancreatic Head Cancer
Not yet recruitingPhase 2
Organoids for Bile Leaks
Biliary Anastomosis Complication
RecruitingObservational study
Efficacy of ABSOLOK™ Clip System-RFP-2021-01 in Open Liver Resection
Bile Leak
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nauzer Forbes, MD, MSc principal investigator
University of Calgary
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Bile Leak, run by University of Calgary at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Absence of persistent bile leak (time frame: immediate). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.